RT Journal Article
SR Electronic
T1 Mitochondrial genome copy number measured by DNA sequencing in human blood is strongly associated with metabolic traits via cell-type composition differences
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.23.20218586
DO 10.1101/2020.10.23.20218586
A1 Ganel, Liron
A1 Chen, Lei
A1 Christ, Ryan
A1 Vangipurapu, Jagadish
A1 Young, Erica
A1 Das, Indraniel
A1 Kanchi, Krishna
A1 Larson, David
A1 Regier, Allison
A1 Abel, Haley
A1 Kang, Chul Joo
A1 Scott, Alexandra
A1 Havulinna, Aki
A1 Chiang, Charleston W. K.
A1 Service, Susan
A1 Freimer, Nelson
A1 Palotie, Aarno
A1 Ripatti, Samuli
A1 Kuusisto, Johanna
A1 Boehnke, Michael
A1 Laakso, Markku
A1 Locke, Adam
A1 Stitziel, Nathan O.
A1 Hall, Ira M.
YR 2021
UL http://medrxiv.org/content/early/2021/02/12/2020.10.23.20218586.abstract
AB Mitochondrial genome copy number (MT-CN) varies among humans and across tissues and is highly heritable, but its causes and consequences are not well understood. When measured by bulk DNA sequencing in blood, MT-CN may reflect a combination of the number of mitochondria per cell and cell type composition. Here, we studied MT-CN variation in blood-derived DNA from 19,184 Finnish individuals using a combination of genome (N = 4,163) and exome sequencing (N = 19,034) data as well as imputed genotypes (N = 17,718). We identified two loci significantly associated with MT-CN variation: a common variant at the MYB-HBS1L locus (P = 1.6×10−8), which has previously been associated with numerous hematological parameters; and a burden of rare variants in the TMBIM1 gene (P = 3.0×10−8), which has been reported to protect against non-alcoholic fatty liver disease. We also found that MT-CN is strongly associated with insulin levels (P = 2.0×10−21) and other metabolic syndrome (metS) related traits. Using a Mendelian randomization framework, we show evidence that MT-CN measured in blood is causally related to insulin levels. We then applied an MT-CN polygenic risk score (PRS) derived from Finnish data to the UK Biobank, where the association between the PRS and metS traits was replicated. Adjusting for cell counts largely eliminated these signals, suggesting that MT-CN affects metS via cell type composition. These results suggest that measurements of MT-CN in blood-derived DNA partially reflect differences in cell-type composition and that these differences are causally linked to insulin and related traits.Competing Interest StatementNOS has received grant funding from Regeneron Pharmaceuticals for unrelated work.Funding StatementThis work was funded by the NHGRI (https://www.genome.gov) Centers for Common Disease Genetics (grant number UM1 HG008853 to IMH and NOS), the NHGRI largescale sequencing grant (grant number 5U54HG003079), the Sigrid Jusélius Foundation (to SR), the University of Helsinki HiLIFE Fellow grants 2017-2020 (to SR), the Academy of Finland Center of Excellence in Complex Disease Genetics (grant number 312062 to SR), the Academy of Finland (grant number 285380 to SR), the National Heart, Lung and Blood Institute (grant number T32HL007081 to EY), and the National Center for Advancing Translational Sciences (grant number UL1TR002345 to EY). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants in both the METSIM and FINRISK studies provided informed consent, and study protocols were approved by the Ethics Committees at participating institutions (National Public Health Institute of Finland; Hospital District of Helsinki and Uusimaa; Hospital District of Northern Savo). All relevant ethics committees approved this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesMETSIM WGS, METSIM WES, and FINRISK WES sequence data are available through dbGaP (accessions phs001579, phs000752, and phs000756). METSIM variant data as well as MT-CN phenotype values will soon be available through AnVIL (accessions TBD). Imputed array GWAS summary statistics from METSIM and WES SKAT-O summary statistics from the joint dataset are freely available at https://wustl.box.com/s/7xfbmxq2r4kg8p8bfc7vpqlrmqvhm0lx. Genomic and phenotypic data for the FINRISK cohort are or will soon be obtainable through THL Biobank, the Finnish Institute for Health and Welfare, Finland (https://thl.fi/en/web/thl-biobank).